Short Interest in Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Drops By 86.4%

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) saw a significant decrease in short interest in March. As of March 31st, there was short interest totaling 61 shares, a decrease of 86.4% from the March 15th total of 449 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 6,216 shares, the days-to-cover ratio is currently 0.0 days.

Bitwise MARA Option Income Strategy ETF Stock Down 2.1%

IMRA traded down $0.29 during trading on Friday, reaching $13.80. The company had a trading volume of 599 shares, compared to its average volume of 6,363. The stock has a market cap of $2.07 million, a P/E ratio of 276.00 and a beta of -3.77. The business has a 50 day simple moving average of $13.78 and a 200-day simple moving average of $20.55. Bitwise MARA Option Income Strategy ETF has a 52 week low of $11.99 and a 52 week high of $60.73.

Insider Transactions at Bitwise MARA Option Income Strategy ETF

In related news, insider Helen Louise Collins sold 40,000 shares of Bitwise MARA Option Income Strategy ETF stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $35.10, for a total value of $1,404,000.00. Following the completion of the transaction, the insider owned 25,000 shares in the company, valued at approximately $877,500. This trade represents a 61.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 37.30% of the stock is currently owned by insiders.

About Bitwise MARA Option Income Strategy ETF

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.